Loading…
for educational and safety purposes
LGD-4033 and LGD-3303 both come up in the same conversations; they overlap on Muscle Growth and Strength. LGD-4033: LGD-4033, also known as ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator, a class of compounds abbreviated as SARM. LGD-3303: LGD-3303 is a non-steroidal selective androgen receptor modulator (SARM) that stands out for its pronounced effects on bone as well as muscle.
LGD-4033, also known as ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator, a class of compounds abbreviated as SARM. It binds the androgen receptor, the same target acted on by testosterone, but is designed to stimulate muscle and bone while having weaker effects on other tissues. First described by Ligand Pharmaceuticals and later developed by Viking Therapeutics, it has been studied for muscle wasting but is not approved for any medical use, and it is banned in sport and sold illicitly to bodybuilders.
LGD-3303 is a non-steroidal selective androgen receptor modulator (SARM) that stands out for its pronounced effects on bone as well as muscle. In rodent studies it raised bone mineral density, stimulated new bone formation, and increased muscle mass while keeping prostate stimulation low, and it even added to the benefit of a standard bone drug. Orally active and strongly tissue-selective, LGD-3303 has a distinctive physique-and-bone profile that keeps it firmly on the radar of SARM research.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Selective tissue-preferential agonist
partial agonist
Dose-dependent suppression of endogenous testosterone
Lowers HDL and SHBG dose-dependently
suppresses
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.